Literature DB >> 8948424

Characterization of the rat vasoactive intestinal polypeptide receptor gene 5' region.

L Pei1, S Melmed.   

Abstract

The broad spectrum of vasoactive intestinal polypeptide (VIP) cellular functions are mediated by high-affinity binding sites. To determine regulation of the VIP receptor gene expression, we have isolated and characterized two genomic clones that contain the first three exons and the 5' flanking region of the VIP receptor gene. Using RNase protection assays, receptor gene expression was detected in adult rat lung, liver and intestine, but not in fetal lung, indicating that VIP receptor is expressed in diverse tissues, and its expression is differentially regulated during lung development. The transcription start site of the gene was mapped to a cytosine residue, 76 bp upstream from the ATG initiation codon. Transfection into rat lung cell lines shows that although 126 bp of the VIP receptor 5' DNA sequences are capable of activating VIP receptor gene basal transcription 30-fold over a promoterless control, 488 bp of the 5' sequences further induce this activation to 97-fold over control. However, inclusion of up to 859 bp 5' sequences results in a decrease in basal promoter activity (31-fold over control), indicating that while sequences between -126 and -488 bp contain potential enhancer sequences, sequences between -488 and -859 bp may include a transcriptional repressor sequence. Deletion analysis shows that transcription factor Sp1 plays an important role in activating basal promoter of the VIP receptor gene. DNase I footprinting and gel-mobility-shift assays show that Sp1 binds to its consensus binding sites in the VIP receptor promoter, suggesting that interaction of Sp1 with VIP receptor promoter transactivates this gene.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8948424      PMCID: PMC1136784          DOI: 10.1042/bj3080719

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  29 in total

1.  Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence.

Authors:  F J Rauscher; J F Morris; O E Tournay; D M Cook; T Curran
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

Review 2.  Heterogeneity of VIP receptors.

Authors:  P Robberecht; A Cauvin; P Gourlet; J Christophe
Journal:  Arch Int Pharmacodyn Ther       Date:  1990 Jan-Feb

3.  Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor.

Authors:  S P Sreedharan; D R Patel; J X Huang; E J Goetzl
Journal:  Biochem Biophys Res Commun       Date:  1993-06-15       Impact factor: 3.575

4.  Selectivity for binding of peptide analogs to vascular receptors for vasoactive intestinal peptide.

Authors:  O P Rorstad; I Wanke; D H Coy; A Fournier; M Huang
Journal:  Mol Pharmacol       Date:  1990-06       Impact factor: 4.436

5.  Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1.

Authors:  I A Drummond; S L Madden; P Rohwer-Nutter; G I Bell; V P Sukhatme; F J Rauscher
Journal:  Science       Date:  1992-07-31       Impact factor: 47.728

6.  The Wilms' tumor gene product, WT1, represses transcription of the platelet-derived growth factor A-chain gene.

Authors:  Z Y Wang; S L Madden; T F Deuel; F J Rauscher
Journal:  J Biol Chem       Date:  1992-11-05       Impact factor: 5.157

7.  A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.

Authors:  T W Moody; F Zia; M Draoui; D E Brenneman; M Fridkin; A Davidson; I Gozes
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

8.  Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide.

Authors:  T Ishihara; R Shigemoto; K Mori; K Takahashi; S Nagata
Journal:  Neuron       Date:  1992-04       Impact factor: 17.173

9.  In vitro differentiation of human neuroblastoma cells caused by vasoactive intestinal peptide.

Authors:  J C Pence; N A Shorter
Journal:  Cancer Res       Date:  1990-08-15       Impact factor: 12.701

10.  Vasoactive intestinal polypeptide binds with high affinity to non-small cell lung cancer cells and elevates cyclic AMP levels.

Authors:  M Lee; R T Jensen; S C Huang; G Bepler; L Korman; T W Moody
Journal:  Peptides       Date:  1990 Nov-Dec       Impact factor: 3.750

View more
  2 in total

1.  The human vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor 1 (VPAC1) promoter: characterization and role in receptor expression during enterocytic differentiation of the colon cancer cell line Caco-2Cl.20.

Authors:  A Couvineau; J J Maoret; C Rouyer-Fessard; I Carrero; M Laburthe
Journal:  Biochem J       Date:  2000-05-01       Impact factor: 3.857

2.  Characterisation of the mouse vasoactive intestinal peptide receptor type 2 gene, Vipr2, and identification of a polymorphic LINE-1-like sequence that confers altered promoter activity.

Authors:  G Steel; E M Lutz
Journal:  J Neuroendocrinol       Date:  2007-01       Impact factor: 3.627

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.